Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

By Sneha S K (Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital ...

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

When the transaction is complete, Bluebird shares will no longer be publicly traded. Pfizer’s Gene Therapy Pullback Continues With Termination of Beqvez Bluebird Bio isn’t the only company ...

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...

Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...